Shots:
- Ipsen enters into a definitive share purchase agreement with ImCheck Therapeutics to acquire later’s all issued and outstanding shares, including lead candidate ICT01, a P-I/II therapy for 1L AML pts ineligible for intensive CT
- As per the deal, shareholders of ImCheck Therapeutics will receive €350M ($406.62M) in closing purchase price, with additional deferred payments tied to regulatory and sales milestones, totaling up to €1B ($1.16B). The deal is expected to close by the end of Q1’26
- ICT01 is a humanized anti-BTN3A mAb that activates γ9δ2 T cells to target tumors. Interim P-I/II EVICTION trial data (n=45) showed strong responses when combined with venetoclax and azacitidine. With Ipsen’s expertise, a Phase IIb/III trial is planned for 2026
Ref: Ipsen| Image: ImCheck Therapeutics | Press Release
Related News:- Medison and Ipsen’s Bylvay Receives the Health Canada’s Approval to Treat Cholestatic Pruritus in Alagille Syndrome Patients
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
